immunotherapy
Preclinical findings will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago.
Emil Chuang, Chief Medical Officer at Intrinsic Medicine, explores the growing understanding of gut-brain axis disorders and the potential of Human Milk Oligosaccharides (HMOs) in their treatment.
The presence of specific microbes in the gut microbiota can serve as biomarkers for predicting the efficacy of immunotherapy.
Specific gut microbiota features correlate with better responses to immunotherapy in people with melanoma.
The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.
Microbiomepost discussed with Lisa Derosa, oncologist at Gustave Roussy Hospital in Paris, about the link between gut dysbiosis and cancer, shedding light on its role in immunotherapy resistance and patient…
The balance of specific microbes in the gut can help predict who will respond to immunotherapy drugs.
The findings of a recent study suggest that the combination of anti-PD-1 immunotherapy with a lack of TREM2 generates a gut environment that promotes inflammation, which improves tumor rejection.
The findings uncover a link between vitamin D, the immune system and gut bacteria, and they suggest that vitamin D levels could be important for cancer immunity and the efficacy…
The findings of a recent study suggest that L. johnsonii or its metabolite IPA could be used as a microbial-based approach to improve a person’s response to immunotherapy.
